bs-23531R [Primary Antibody]
phospho-Nrf2 (Ser40) Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: phospho-Nrf2 (Ser40)

Modification Site: Ser40

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 4780

Swiss Prot: Q16236

Source: KLH conjugated synthetic peptide derived from human phospho-Nrf2 (Ser40)

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. Important for the coordinated up-regulation of genes in response to oxidative stress. May be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF()
ICC(1:100-500)

Predicted Molecular Weight: 68


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog
Cow
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Yueqi Yang. et al. A Compared Study of Eicosapentaenoic Acid and Docosahexaenoic Acid in Improving Seizure-Induced Cognitive Deficiency in a Pentylenetetrazol-Kindling Young Mice Model. MAR DRUGS. 2023 Sep;21(9):464Read more>>
  • Liu Yujia. et al. Aerobic exercise improves BKCa channel-mediated vasodilation in diabetic vascular smooth muscle via AMPK/Nrf2/HO-1 pathway. ACTA DIABETOL. 2023 Dec;:1-1Read more>>
VALIDATION IMAGES

Lane 1: Mouse Spleen tissue lysates; Lane 2: Human HepG2 cell lysates; Lane 3: Human Hela cell lysates; Lane 4: Mouse BV-2 cell lysates probed with phospho-Nrf2 (Ser40) Polyclonal Antibody, Unconjugated (bs-23531R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.